If you or a loved one has been living with depression that hasn’t responded to traditional antidepressant medications, you may have started researching alternative treatment options. Spravato treatment in Chicago is one such option that has generated significant interest among patients and mental health providers alike. As an FDA-approved nasal spray therapy, Spravato (esketamine) offers a different mechanism of action than conventional antidepressants and may provide relief for individuals who have not found success with other approaches.
At Innovative MindCare, we understand that exploring a newer treatment can come with many questions. This FAQ guide is designed to provide clear, helpful answers about Spravato therapy, including who may be eligible, what a typical session involves, insurance considerations, and what distinguishes this treatment from other options. Whether you are located in Chicago or Downers Grove, we hope these answers help you feel more informed as you consider your next steps.
Spravato is the brand name for esketamine, a nasal spray that was approved by the U.S. Food and Drug Administration (FDA) for specific depression-related conditions. It is derived from ketamine but is a distinct pharmaceutical product with its own regulatory classification and approved clinical indications. Spravato is not a general-purpose antidepressant; rather, it is specifically indicated for two populations:
Spravato works on the glutamate system in the brain, which is different from the serotonin- and norepinephrine-based mechanisms targeted by most traditional antidepressants. This alternative pathway is believed to help promote new neural connections and may contribute to symptom improvement in patients who have not benefited from conventional medications.
Eligibility for Spravato is determined on a case-by-case basis by a qualified healthcare provider. In general, candidates include adults aged 18 and older who have been diagnosed with treatment-resistant depression or who are experiencing major depressive disorder with suicidal ideation. To qualify for TRD treatment, a patient typically must have tried at least two prior antidepressant therapies without achieving adequate improvement.
It is important to note that Spravato is prescribed in conjunction with a newly initiated or currently prescribed oral antidepressant – it is not intended to be used as a standalone therapy. During your initial consultation at Innovative MindCare, your provider will review your full medical and psychiatric history, current medications, and treatment goals to determine whether Spravato is an appropriate option for you.
Certain medical conditions, including uncontrolled hypertension, a history of aneurysmal vascular disease, or a history of intracerebral hemorrhage, may affect eligibility. Your provider will discuss any contraindications during the evaluation process.
One of the most common questions we receive about Spravato treatment in Chicago is what a typical session looks like. Because Spravato is part of the FDA’s Risk Evaluation and Mitigation Strategy (REMS) program, it must be administered in a certified healthcare setting under direct medical supervision. Patients cannot take the medication at home.
Here is a general overview of what to expect during a session at Innovative MindCare:
Spravato treatment follows a structured schedule that is typically divided into phases:
The exact duration and frequency of your treatment plan will be personalized by your provider at Innovative MindCare based on your individual progress and clinical needs. Some patients may require ongoing maintenance sessions, while others may eventually be able to reduce the frequency of treatments over time.
Yes. As an FDA-approved treatment, Spravato is typically covered by major insurance providers. At Innovative MindCare, we accept the following insurance plans for Spravato treatment:
This broad range of accepted insurance plans helps make Spravato treatment in Chicago and Downers Grove more accessible to a wider population of patients. If you have questions about whether your specific plan is accepted, we encourage you to contact our office directly for guidance.
Innovative MindCare offers Spravato treatment at our locations serving patients in Chicago and Downers Grove, Illinois. Both locations are equipped with the certified clinical environments required under the REMS program, and our trained medical staff are experienced in administering and monitoring Spravato therapy. Whether you live in the city or the surrounding suburbs, our clinics are designed to provide a comfortable, supportive setting for your treatment sessions.
As with any medication, Spravato may cause side effects. The most commonly reported side effects include:
Most side effects are temporary and tend to resolve within the two-hour monitoring period. The requirement that patients remain in the clinic after each session is specifically designed to ensure safety and allow the care team to manage any adverse reactions that may arise. Your provider at Innovative MindCare will discuss all potential risks and side effects with you before beginning treatment.
One of the aspects that has drawn clinical interest to Spravato is the potential for a relatively rapid onset of symptom improvement compared to many traditional antidepressants, which can take several weeks to take effect. Some patients have reported noticing changes within the first few sessions, though individual responses vary widely. It is important to set realistic expectations – not every patient will respond to Spravato, and results are not guaranteed. Your provider will closely monitor your progress throughout the treatment process and make adjustments to your care plan as needed.
This is one of the most frequently asked questions, and the distinction is important. While Spravato (esketamine) is chemically related to ketamine, they are different treatments with different regulatory and clinical frameworks:
Innovative MindCare offers both Spravato and IV ketamine therapy, so our clinical team is well-positioned to help patients explore the option that best aligns with their diagnosis, treatment history, and goals.
Living with treatment-resistant depression or major depressive disorder with suicidal ideation can feel overwhelming, especially when previous treatments have not delivered the relief you were hoping for. Spravato treatment in Chicago at Innovative MindCare provides a structured, medically supervised option that has been shown to help many patients experience meaningful improvement in their depressive symptoms.
We hope this FAQ has helped answer some of your most pressing questions. Every patient’s situation is unique, and the best way to determine whether Spravato is right for you is through a personalized consultation with a qualified provider. Our team at Innovative MindCare, serving patients in Chicago and Downers Grove, is here to provide the information and clinical expertise you need to make an informed decision about your mental health care.
If you would like to learn more about Spravato treatment or schedule a consultation, we encourage you to reach out to Innovative MindCare today. Our team is ready to answer any additional questions and help you explore whether this treatment may be a suitable option for your journey toward improved well-being.